Image description

Published yearly: 

4 Issues

______________________

ISSN: 2320-964X (Online) 

ISSN: 2320-7817  (Print)

______________________

Editor-in-Chief

Dr. Santosh Pawar 


INDEXED IN

RESEARCH ARTICLE

_______________________________________________________________________________________

Int. Journal of Life Sciences, 2018; 6(4): 885-894      |                 Available online, December 22, 2018

Structural and functional characterization of BAP1 human protein

 

Rawal Jyoti, Sharma Rekha and Sharma Priyal

 

Department of Zoology, Holkar Science College, Indore, MP, India

 

 

Received: 25.01.2018    |   Revised: 07.04.2018   |  Accepted: 03.12.2018   |   Published: 22.12.2018

Cancer is a deadly disease in humans and arises from uncontrolled cell division. Cancer are broadly therefore, categorized into two types: primary cancers (in the organ or tissue where cancer originated) and secondary cancers (metastatic tumor). In 1990, the first breast cancer susceptibility gene BRCA1 was identified on chromosome 17q12-21 by linkage analysis of multiple families affected by early onset breast and ovarian cancer. BRCA1 is large spread over 80 kb genomic DNA composed of 24 exons, 22 codings and 2 non-coding exons that are transcribed into a 7.8 kb mRNA encodes a protein containing 1863 amino acids. The approximate molecular mass of the BRAC1 protein is 220 kDa. The BRCA1 gene bears no homology with other genes, with the exception of a RING finger motif at the amino-terminal end. In other proteins such a motif has been shown to interact with nucleic acids and to from protein complexes, suggesting a role of BRCA1 in transcription. Nuclear localization sequence in exon 11, and a conserved acidic carboxy terminus, the BRCT (BRCA1 carboxyl terminal) domain. Till date, more than 800 different mutations mostly frame shift mutations in the BRCA1 gene have been reported. BRCA1 gene contains N-terminal RING finger domain and two C-terminal BRCT (BRCA1-C-Terminal) domain, both involved in protein-protein interactions. Exon 11 of BRCA1 gene contains over 60% of protein and encodes two putative localization signals, also contain a domain that interacts with RAD51, a homology of E. Coli rec. a involved in DNA damage repair. BRACA1 was associated and co-purified with RNA polymerase complex, and interacts with RNA helicase in a transcription Germline mutation in BRCA1 has been detected in approximately 80-90% of familial breast/ovarian cancer and about 45-50% of familial breast cancer alone.

 

Keywords: Heteroresistance, Multidrug resistant tuberculosis, Extensively drug resistant tuberculosis, rpoB gene

 

 

_________________________________________________________________________

Editor: Dr.Arvind Chavhan

___________________________________________________________________________________ 

Cite this article as:

Rawal Jyoti, Sharma Rekha and Sharma Priyal (2018) Structural and functional characterization of BAP1 human protein, Int. J. of. Life Sciences, Volume 6(4): 885-894. 

____________________________________________________________________________

Acknowledgement

All the authors are very thankful to Principal, Janata Mahavidyalaya, Chandrapur for providing the full research facilities to conduct the present work.

____________________________________________________________________________


Conflicts of interest: The authors stated that no conflicts of interest.

____________________________________________________________________________

 

Copyright: © 2018 | Author(s), This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial - No Derives License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

_________________________________________________________________________

Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene.25, 5898-5905.


Atlas E, Stramwasser M, Whiskin K, and Mueller CR (2000) GA-binding protein alpha/beta is a critical regulator of the BRCA1 promoter. Oncogene. 19:1933-40.


Balakirev MY, et al. (2003) Otubains: a new family of cysteine proteases in the ubiquitin pathway.


Beger C, Pierce LN, Kruger M, Marcusson EG, Robbins JM, Welcsh P, Welch PJ, Welte K, King MC, Barber JR and Wong- Staal F (2001) Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc. Natl Acad. Sci. USA, 98, 130–135.


Birnboim HC and J Doly (1979) A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Research 7:1513-1523.


Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F and Shiekhattar R (2000) BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell.102:257-65.


Burrows JF et al. (2004) DUB3, a cytokine inducible deubiquitinating enzyme that blocks proliferation. Journal of Biological Chemistry. 279(14):13993-14000.


Chen CF, Li S, Chen, Chen PL, Sharp PZ and Lee WH (1996) The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J Biol Chem. 271:32863-8.


Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne CK and Lee WH (1995) Aberrant sub cellular localization of BRCA1 in breast cancer. Science. 270:789-91.


Chung CH, Baek SH (1999) Deubiquitinating enzymes: their diversity and emerging roles. Biochemical and biophysical research communications. 266(3): 633-640.


Collins FS, Merajver SD, pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL et al. (1995) Somatic mutations in the BRCA1 gene in sporadic ovarian tumors Nat. Genet., 9 (1995), pp. 439-443.


Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF et al. (1995) Con-sistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12–13. Oncogene, 10, 1673–1675.


Easton DF, Bishop DT, Ford D, Crockford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast cancer linkage consortium, American Journal of human genetics. 52(4):678-701. EMBO reports. 4(5):517-522.


Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen Y et al. (1994). BRCA1 mutations in primary breast and ovarian carcinomas. Science. 266:120-2.


Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B and King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science, 250, 1684–1689.


Harold J, Burstein MD, Eric P, Winer MD (2000) Primary care for Survivors of Breast Cancer. N Engl J Med.343:10.


Jemal A, et al. (2011) Global cancer statistics. CA: a cancer Journal for clinicians. 61(2) 69-90.

Jennifer LK, Marilie D (2000) Gammon. The epidemiology of breast cancer CA-A. Cancer journal for Clinicals.146-165.


Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, Olsson H, Trent JM, Isola J and Borg A (2000) MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res., 60, 5323–5328.


Kim HT, et al. (2007) Certain pairs of ubiquitin conjugating enzymes (E2s) and ubiquitin protein ligases (E3s) synthesize non degradable forked ubiquitin chains containing all possible isopeptide linkages. Journal of Biological Chemistry. 282(24): 17375-17386.


Kim JH, et al. (2003) Deubiquitinating enzymes as cellular regulators. Journal of biochemistry.134 (1):9-18

Laemmli UK. (1970) Cleavage of structural protein during assembly of the head of bacteriophage T4. Nature; 22:680-685.


Li S, Ting NS, Zheng L, Chen PL, Ziv Y, Shiloh Y, Lee EY and Lee WH (2000) Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature, 406, 210–215.


Martin AM and Weber L (2000) Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst. 92:1126-35.


Miki Y, Swensen J, Shattuck-Eiden D, Futreal PA, Haeshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266,66-71.


Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer Cancer Invest. 26: 1-10.


Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. (2002) Radiation effects on breast cancer risk: a pooled analysis of eight cohorts Radiat. Res.158(2):220-35.


Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF (2006) Molecular classification of breast cancer: limitations and potential, Oncologist. 11:868-877.


Ruffner H, Jiang W, Craig AG, Hunter T and Verma IM (1999) BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol. Cell. Biol., 19, 4843–4854.


Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, et al. (1997) BRCA1 is a component of the RNA polymerase II holo enzyme. Proc Natl Acad Sci USA 1997;94:5605-10.


Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75.


Welcsh PL, Owens KN and King MC (2000) Insights into the functions of BRCA1 and BRCA2.Trends Genet., 16, 69-74.


Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2.Nature, 378, 789–792.


Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D. et al. (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science, 265, 2088–2090


Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, et al. (1999) Centrosome amplification and a defective G2-M cell cycle check point induce genetic instability in BRCA1 exon 11 isoform-deficient cells. MOl Cell 1999;3:389-95.

 

 

IJLSCI EVENTS

ADVERTISEMENT

 
















    INTERNATIONAL JOURNAL OF

    LIFE SCIENCES


    Print ISSN : 2320-7817 

    Online ISSN:2320-964X



    EDITORIAL OFFICE

    46, Guruwandan, Jawahar Nagar, 

    VMV Road, Amravati- 444604

    Maharashtra, India.

    Tel  + 91- 9970559438  |   9420775527  

    Email: editor@ijlsci.in | editorijlsci@gmail.com